Hiroshi Ishiguro

Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers

Masashi Kanai, Atsushi Imaizumi, Yoshihiko Otsuka et al. · Cancer Chemotherapy and Pharmacology · 2011 · 253 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial

Akiko Hanai, Hiroshi Ishiguro, Takashi Sozu et al. · JNCI Journal of the National Cancer Institute · 2017 · 134 citations · Full text

Medicine, Oncology, Pharmacology +15

Economic evaluation of the 21-gene signature (Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)

Masahide Kondo, Shu-Ling Hoshi, Takeharu Yamanaka et al. · Breast Cancer Research and Treatment · 2010 · 74 citations

Medicine, Oncology, Breast Oncology +12

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial

Masakazu Toi, Shigeru Imoto, Takanori Ishida et al. · The Lancet Oncology · 2020 · 62 citations

Medicine, Endocrinology, Oncology +16

Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan

Masahide Kondo, Shu Ling Hoshi, Hiroshi Ishiguro et al. · Breast Cancer Research and Treatment · 2007 · 52 citations

Medicine, Oncology, Breast Oncology +7